MERIBEL PHARMA PROVENCE : revenue, balance sheet and financial ratios

MERIBEL PHARMA PROVENCE is a French company founded 42 years ago, specialized in the sector Fabrication de produits pharmaceutiques de base. Based in SALON-DE-PROVENCE (13300), this company of category ETI shows in 2024 a revenue of 10.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - MERIBEL PHARMA PROVENCE (SIREN 329541411)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 10 791 867 € 10 575 876 € 9 282 514 € 7 135 948 € 6 123 273 € 5 952 047 € 5 163 187 € 5 186 151 € 5 795 869 €
Net income 1 271 747 € 1 384 370 € 1 371 766 € 838 602 € 714 838 € 616 189 € 637 855 € 406 420 € 381 398 €
EBITDA 2 539 916 € 2 534 381 € 2 008 276 € 1 352 128 € 888 838 € 757 068 € 665 158 € 349 303 € 768 849 €
Net margin 11.8% 13.1% 14.8% 11.8% 11.7% 10.4% 12.4% 7.8% 6.6%

Revenue and income statement

In 2024, MERIBEL PHARMA PROVENCE achieves revenue of 10.8 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +8.1%. Vs 2023: +2%. After deducting consumption (446 k€), gross margin stands at 10.3 M€, i.e. a rate of 96%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 2.5 M€, representing 23.5% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.3 M€, i.e. 11.8% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

10 791 867 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

10 345 404 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

2 539 916 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

2 042 029 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 271 747 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

23.5%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 3%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 42%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 18.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

3.237%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

42.44%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

18.942%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.074

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

51.8%

Solvency indicators evolution
MERIBEL PHARMA PROVENCE

Sector positioning

Debt ratio
3.24 2024
2022
2023
2024
Q1: 0.0
Med: 3.24
Q3: 65.34
Good +24 pts over 3 years

In 2024, the debt ratio of MERIBEL PHARMA PROVENCE (3.24) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
42.44% 2024
2022
2023
2024
Q1: 17.24%
Med: 45.12%
Q3: 75.14%
Average -6 pts over 3 years

In 2024, the financial autonomy of MERIBEL PHARMA PROVENCE (42.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
0.07 years 2024
2022
2023
2024
Q1: -1.5 years
Med: 0.0 years
Q3: 1.31 years
Average

In 2024, the repayment capacity of MERIBEL PHARMA PROVENCE (0.07) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 37.51. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 10.3x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

37.51

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

10.346

Liquidity indicators evolution
MERIBEL PHARMA PROVENCE

Sector positioning

Liquidity ratio
37.51 2024
2022
2023
2024
Q1: 92.26
Med: 208.82
Q3: 371.21
Watch

In 2024, the liquidity ratio of MERIBEL PHARMA PROVENCE (37.51) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
10.35x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.82x
Q3: 13.45x
Good

In 2024, the interest coverage of MERIBEL PHARMA PROVENCE (10.3x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 45 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 67 days. Favorable situation: supplier credit is longer than customer credit by 22 days. Inventory turnover is 10 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. WCR is negative (-151 days): operations structurally generate cash. Notable WCR improvement over the period (-1445%), freeing up cash.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

-4 517 152 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

45 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

67 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

10 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

-151 j

WCR and payment terms evolution
MERIBEL PHARMA PROVENCE

Positioning of MERIBEL PHARMA PROVENCE in its sector

Comparison with sector Fabrication de produits pharmaceutiques de base

Similar companies (Fabrication de produits pharmaceutiques de base)

Compare MERIBEL PHARMA PROVENCE with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de produits pharmaceutiques de base

Frequently asked questions about MERIBEL PHARMA PROVENCE

What is the revenue of MERIBEL PHARMA PROVENCE ?

The revenue of MERIBEL PHARMA PROVENCE in 2024 is 10.8 M€.

Is MERIBEL PHARMA PROVENCE profitable?

Yes, MERIBEL PHARMA PROVENCE generated a net profit of 1.3 M€ in 2024.

Where is the headquarters of MERIBEL PHARMA PROVENCE ?

The headquarters of MERIBEL PHARMA PROVENCE is located in SALON-DE-PROVENCE (13300), in the department Bouches-du-Rhone.

Where to find the tax return of MERIBEL PHARMA PROVENCE ?

The tax return of MERIBEL PHARMA PROVENCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does MERIBEL PHARMA PROVENCE operate?

MERIBEL PHARMA PROVENCE operates in the sector Fabrication de produits pharmaceutiques de base (NAF code 21.10Z). See the 'Sector positioning' section above to compare the company with its competitors.